Unmet Need: Targeted treatment for inflammatory diseases
Inflammation is an immune response usually caused by trauma or infection. When dysregulated, inflammation can cause diseases such as acute lung inflammation (ALI) leading to acute respiratory distress syndrome (ARDS). There are over 200,000 cases of ARDS annually in adults in the United States, however, there are no approved therapeutics for this disease.
The Technology: Targeted delivery of resolvin precursors to resolve inflammation without suppressing the immune response
The inventors have developed a lung-targeted therapeutic utilizing omega-3 fatty acids which metabolize to resolvins to treat acute inflammation, specifically ALI/ARDS. Resolvins are a type of biomolecule that help resolve inflammation in tissue, as opposed to suppressing immune response. Unfortunately, they are difficult to synthesize and sensitive to oxidation. The inventors have developed a method to deliver a resolvin precursor, docosahexaenoic acid (DHA), to inflamed lung tissue where it is metabolized to resolvins. The treatment utilizes newly designed liposomes, loaded with DHA and coated with a neutrophil-targeting antibody to specifically target activated neutrophils in vivo.
- Treatment of inflammation
- Acute lung inflammation and
acute respiratory distress syndrome treatment
- Targeted delivery reduces side effects
- Does not suppress the immune response
- In vivo production of resolvins reduces degradation
Provisional patent filed
TTO Home Page: https://wsu.technologypublisher.com
Name: Scott Steiger
Title: Assistant Director
Department: Office of Commercialization
Phone: (509) 335-7065